AML harboring TP53, RUNX1, ASXL1, and RAS mutations, found in the adverse-risk category, exhibits a higher immune effector dysfunction (IED172) score and an IFNγ signature, the latter being associated with a positive response to azacytidine (AZA) + pembrolizumab [75]. This evidence concerns the gene TP53 and acute myeloid leukemia.